Trial
NCT02949843
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Wake Forest University Health Sciences
Collaborators
National Cancer Institute (NCI)
Condition
EGFR Activating Mutation
Intervention
Chemotherapy
Why stopped
Slow accrual, closed by IRB
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-28